Australian (ASX) Stock Market Forum

OCC - Orthocell Limited

Jump to new
Orthocell Limited (OCC) appears to be threatening for a breakout to the upside and, as such, is a personal stock selection for the February stock competition here at ASF. Referring to the daily chart below, we have the share price closing above the 10 and 30 day MA's at the end of the final complete trading week of the January calendar month, whilst also closing above two recent opens which could potentially act as support/resistance areas from 6th January and 10th January ($1.53 and $1.495, respectively). A supportive DMI/ADX and RSI also assist a potentially bullish perspective from a technical analysis aspect.

1737865640819.png
 
Price continuing to hold strongly after rise to $1.50 in late Deceember '24.

Recent approval for Remplir in Singapore should pass on in the next few months to Thailand who recognize each others approvals. Both these countries are destination countries for medical procedures from people throughout South East Asia.

Then we wait for Remplir approval in America by mid-year.
 
access said:
Price continuing to hold strongly after rise to $1.50 in late Deceember '24.

Recent approval for Remplir in Singapore should pass on in the next few months to Thailand who recognize each others approvals. Both these countries are destination countries for medical procedures from people throughout South East Asia.

Then we wait for Remplir approval in America by mid-year.
Click to expand...
Closed at a record high today.
 
On Friday, Orthocell (ASX:OCC) secured a major commercial milestone, receiving US FDA 510(k) clearance for its flagship nerve repair product, Remplir™, allowing immediate sales into the US market. Remplir is a collagen-based nerve wrap designed to assist surgeons in repairing and regenerating damaged peripheral nerves. This approval gives Orthocell access to the US$1.6bn US nerve repair market, which it sees as a significant commercial inflection point expected to drive the company towards breakeven and future profitability.

The company has prepared extensively for this moment, with a US executive team already in place, logistics infrastructure set up, and a production facility in Perth capable of manufacturing 100,000 units per year. Orthocell has no debt or royalty obligations on Remplir, so it retains full margins.

It plans to roll out its US commercial strategy using a mix of in-house leadership and regional distributor networks, targeting up to 12 partners within 6–12 months.

Screenshot_20250405_104033_CommSec~2.jpg
 
Remplir now having regular approval for use in a range of countries. Smrtgraft will be next big product to get approval.
 
Share price is being held back until end of quarter figures are released to verify the sales that people are expecting to be taking place.

A massive market for their products and all being manufactured in Australia.
 


Write your reply...
Top